<DOC>
	<DOCNO>NCT01155661</DOCNO>
	<brief_summary>The primary objective study evaluate long-term safety tolerability LY2216684 administer daily ( QD ) adjunctive treatment selective serotonin reuptake inhibitor ( SSRI ) approximately 1 year patient major depressive disorder ( MDD ) partial responder SSRI treatment .</brief_summary>
	<brief_title>A Safety Study Patients With Major Depressive Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Serotonin Uptake Inhibitors</mesh_term>
	<mesh_term>Phenylethyl Alcohol</mesh_term>
	<criteria>Adults competent able give inform consent Women childbearing potential may participate must test negative pregnancy time study entry ; women/men agree use reliable method birth control Patients treat one follow SSRIs : escitalopram , citalopram , sertraline , fluoxetine , paroxetine , fluvoxamine ; least 6 week prior investigational product dispense least last 4 week stable , optimized dose Drug dosage within label guideline specific country Meet criterion MDD ( Major Depressive Disorder ) , define Diagnostic Statistical Manual , Fourth Edition , Text Revision ( DSMIVTR ) criteria Meet criterion partial response , define investigator 's opinion patient experience minimal clinically meaningful improvement SSRI Have Grid Hamilton Rating Scale Depression ( GRIDHAMD17 ) total score great equal 16 screen Have le equal 75 percent improvement current SSRI screening determine Massachusetts General Hospital Antidepressant Response Questionnaire ( MGHATRQ ) Meet inclusion criterion per protocol Presence another primary psychiatric illness : Have currently additional ongoing DSMIVTR Axis 1 condition major depression within 1 year screening Have anxiety disorder consider primary diagnosis within past year ( include panic disorder , obsessivecompulsive disorder , posttraumatic stress disorder , generalize anxiety disorder , social phobia , exclude specific phobia ) Have current previous diagnosis bipolar disorder , schizophrenia , psychotic disorder Have history substance abuse and/or dependence within past 1 year ( drug category define DSMIVTR ) , include caffeine nicotine Have Axis II disorder , judgment investigator , would interfere compliance protocol Unstable medical condition contraindicate use LY2216684 Have diagnose medical condition could exacerbate noradrenergic agent include unstable hypertension , unstable heart disease , tachycardia , tachyarrhythmia , narrowangled glaucoma , urinary hesitation retention Use exclude concomitant psychotropic medication SSRI Have initiate discontinue hormone therapy within previous 3 month prior enrollment History treatment resistant depression show : Have lack response current depressive episode 2 adequate course antidepressant therapy clinically appropriate dose least 4 week , judgment investigator , patient treatmentresistant depression Have history electroconvulsive therapy , transcranial magnetic stimulation , psychosurgery within last year Meet exclusion criterion per protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>